EcoR1 Capital exits Tango Therapeutics (TNGX) reporting with 0% ownership
Rhea-AI Filing Summary
Tango Therapeutics, Inc. (TNGX) received an amended Schedule 13G/A showing that EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman now report zero beneficial ownership of the company’s common stock. As of December 31, 2025, each reporting person lists 0 shares beneficially owned and a 0% stake, with no sole or shared voting or dispositive power. The filing confirms they own 5 percent or less of the class. The parties also state they are filing jointly but expressly disclaim being part of a group and disclaim beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
EcoR1 and affiliates report 0% ownership in Tango Therapeutics common stock as of December 31, 2025.
The filing shows EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman each reporting 0 shares of Tango Therapeutics common stock beneficially owned, corresponding to 0% of the class. They also report no sole or shared voting or dispositive power.
The statement notes ownership of 5 percent or less of the class, indicating they no longer meet the threshold for significant holder reporting. The parties file jointly but expressly disclaim group status and beneficial ownership beyond any pecuniary interest. Subsequent filings may clarify any future changes in ownership.
FAQ
What does EcoR1 Capital report owning in Tango Therapeutics (TNGX)?
Which investors are listed as reporting persons in this Tango Therapeutics (TNGX) Schedule 13G/A?
What percentage of Tango Therapeutics (TNGX) does EcoR1 Capital now own?
Are EcoR1 Capital and Oleg Nodelman filing as a group for Tango Therapeutics (TNGX)?
What is the event date for EcoR1’s amended ownership report in Tango Therapeutics (TNGX)?
How does this Schedule 13G/A affect EcoR1’s status in Tango Therapeutics (TNGX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.